Pfizer Inc. (NYSE: PFE) announced positive topline results from two pivotal Phase 3 trials evaluating LITFULO (ritlecitinib) for nonsegmental vitiligo (NSV), with both studies meeting their co-primary endpoints. The TRANQUILLO and TRANQUILLO 2 trials demonstrated statistically significant improvements in facial and total body repigmentation versus placebo at Week 52, supporting Pfizer’s plan to submit global regulatory filings for the oral systemic therapy. This development addresses a chronic autoimmune disease characterized by pigment loss, offering a potential new treatment option beyond topical therapies.

The clinical program enrolled 2,174 patients across 271 sites worldwide, representing the largest Phase 3 program to date for an oral systemic therapy in this indication. TRANQUILLO included 607 adults and adolescents aged 12 years and older, while TRANQUILLO 2 enrolled 1,567 adults only. Both trials evaluated patients with active or stable NSV across a broad range of disease severity. In the United States, co-primary endpoints were defined as the proportion of patients achieving ≥75% improvement in Facial Vitiligo Area Scoring Index (F-VASI75) and ≥50% improvement in Total Vitiligo Area Scoring Index (T-VASI50) from baseline at Week 52.

Michael Vincent, M.D., Ph.D., Chief Inflammation & Immunology Officer at Pfizer, stated that LITFULO’s unique mechanism targets TEC family kinases and JAK3, contributing to its distinct clinical profile. He noted that the positive results build on the company’s expertise in dermatology and existing experience with LITFULO in severe alopecia areata. Vincent emphasized that if approved, LITFULO could become a new oral systemic treatment option that significantly improves and potentially maintains repigmentation for adults living with NSV.

The safety profile of LITFULO in NSV was consistent with its established profile in alopecia areata, with no new safety signals observed. The proportion of patients experiencing treatment-emergent adverse events was similar across all treatment groups. Iltefat Hamzavi, M.D., Senior Staff Physician at Henry Ford Health, highlighted that many patients seek additional options due to the unpredictable nature of NSV and limitations of current treatments. She noted that the trial findings reinforce the potential of LITFULO to support a new treatment paradigm with systemic therapies for patients whose disease burden warrants more than localized treatment alone.

What the Numbers Show

The scale of the clinical evidence is a key differentiator for this development. By enrolling 2,174 patients across two pivotal trials, Pfizer has generated a robust dataset for an oral systemic therapy in nonsegmental vitiligo, an area historically dominated by topical treatments or off-label systemic immunosuppressants. The dual-endpoint success—achieving both significant facial repigmentation (F-VASI75) and total body improvement (T-VASI50)—suggests a broad efficacy profile that addresses both highly visible areas and overall disease burden. This comprehensive data package positions Pfizer to pursue global regulatory approvals, potentially expanding the commercial footprint of LITFULO beyond its current indication in severe alopecia areata, which was approved by the U.S. Food and Drug Administration in 2023.

Pfizer Inc. and BioNTech SE announced on July 29, 2026, that the European Commission (EC) has granted marketing authorization for their 2026-2027 COVID-19 vaccine formula. The monovalent vaccine targets the XFG variant of the JN.1 lineage and is approved for active immunization against SARS-CoV-2 in individuals aged 6 months and older. This authorization is valid across all 27 European Union Member States, as well as Iceland, Liechtenstein, and Norway, ensuring broad regional access ahead of the upcoming respiratory disease season.

The approval follows a recommendation from the Emergency Task Force (ETF) of the European Medicines Agency (EMA), which stated that targeting the XFG variant would provide the best protection against COVID-19. The EC decision was based on the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommendation issued on July 23, 2026. The CHMP’s assessment relied on a cumulative body of evidence submitted by Pfizer and BioNTech, including clinical, non-clinical, and real-world data supporting the safety and efficacy of the vaccine.

Immune Response and Variant Coverage

Data indicate that the 2026-2027 vaccine formula induces a strong immune response against contemporary circulating and emerging lineages. The monovalent XFG-adapted vaccine demonstrated efficacy against several key sublineages, as detailed below:

Supply Readiness and Distribution

Pfizer and BioNTech have already initiated manufacturing of the monovalent XFG-adapted COVID-19 vaccine at risk to ensure supply readiness. Shipping is set to begin soon to ensure rapid access for the current season, anticipating increased demand during the respiratory disease season. EU Member States and Norway will be supplied either via the EC contract or according to individual country government policies.

The companies have also submitted data for the updated COVID-19 vaccine to regulatory authorities around the world and are continuing to monitor the evolving epidemiology of COVID-19 to meet global public health needs. More than five billion doses of Pfizer-BioNTech COVID-19 vaccines have been distributed globally since the program's inception.

Technology and Authorization Holder

The COVID-19 vaccines developed by Pfizer and BioNTech are based on BioNTech's proprietary mRNA technology and were developed jointly by both companies. BioNTech serves as the Marketing Authorization Holder for the Pfizer-BioNTech COVID-19 vaccine and its adapted vaccines in the United States, the EU, the United Kingdom, and other countries. BioNTech also holds emergency use authorizations or equivalents in other jurisdictions.